Senior Commercial Associate, Evox

  • Promoted to Senior Commercial Associate after showing strong performance and a track record of surpassing ambitious goals; supported senior leadership team in US$95m Series C fundraising (Feb 2021)

  • Second member on the BD team; part of a core deal team which won a US$880m collaboration with Takeda (

    (a top 5 largest Japanese conglomerate) and a US$1.2bn collaboration with Eli Lilly & Co (a top 10 US pharmaceutical company)

  • Led on deal metrics and ROI for strategic projects, which formed the basis for the Board’s decision to pursue select partnerships; supported the VP of Business Development in licensing agreement reviews and negotiations

  • Represented Evox externally and delivered company presentations at major industry events

  • Spearheaded Evox’s early stage product expansion by establishing a collaboration with the University of Oxford (Nov 2020); managed and led process end-to-end from creating a business case, negotiating the contract, overseeing project selection and engaging with the C-level joint Evox-Oxford board

  • Led negotiations enabling existing product development with a range of partners (suppliers, commercial partners, academic collaborators and VC firms)

Founder & CEO, Zelta Technologies

  • Led a team of three including a machine learning engineer and a UI/UX designer to create a neural network prototype

  • Zelta secured long-term contracts to advise Oxehealth, a University of Oxford digital health spin-out focused on activity tracking and remote vital sign monitoring amongst elderly and vulnerable patients

  • Contributed to Oxehealth’s product and commercial roadmap by shadowing their clients and translating on-the-ground feedback into recommendations for the Product, Engineering and Commercial teams

  • Led on US market entry research within the USA - segmented potential customers based on organisation type and performed an extensive analysis on healthcare metrics across various USA geographies; results of this analysis laid the foundation for strategic decisions in relation to USA expansion

  • Supported the Sales team by crafting detailed quantitative analyses on the financial and clinical impact of Oxehealth’s technology; findings formed the basis for supporting Oxehealth’s business case and expanding two key accounts. After a successful completion of this contract, I joined Evox’s commercial team

Investment Banker, Centerview

  • Advised Fortune 500 clients on mergers & acquisitions and strategic sales of business assets

  • Responsible for coordinating the deal execution process with key stakeholders, keeping a 30-person team on track

  • Part of a 4-person team which launched the US$650m Takeda-TiGenix deal (the largest Belgian merger deal in 2018); led on advanced financial modelling analysis which formed the basis for share price negotiations

  • Built expertise in the field of value creation through corporate strategy backed up by in-depth data driven approaches

  • Crafted strategic advisory papers for a FTSE100 company’s Board meetings